Journal
CANCER CELL
Volume 1, Issue 5, Pages 433-443Publisher
CELL PRESS
DOI: 10.1016/S1535-6108(02)00069-7
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA66996] Funding Source: Medline
- NIDDK NIH HHS [P01 DK50654] Funding Source: Medline
Ask authors/readers for more resources
Constitutively activating FLT3 receptor mutations have been found in 35% of patients with acute myeloblastic leukemia (AML). Here we report the identification of a small molecule Fill tyrosine kinase inhibitor PKC412, which selectively induced G1 arrest and apoptosis of Ba/F3 cell lines expressing mutant FLT3 (IC50 < 10 nM) by directly inhibiting the tyrosine kinase. Ba/F3-FLT3 cell lines made resistant to PKC412 demonstrated overexpression of mutant FLT3, confirming that FLT3 is the target of this drug. Finally, progressive leukemia was prevented in PKC412-treated Balb/c mice transplanted with marrow transduced with a FLT3-ITD-expressing retrovirus. PKC412 is a potent inhibitor of mutant Ill and is a candidate for testing as an antileukemia agent in AML patients with mutant FLT3 receptors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available